Physician profile
Robert N Earle
NPI 1750506986
$2,893.29
in general payments reported to CMS, 2019-2025
24 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $506 · 2021: $23.18 · 2022: $307 · 2023: $726 · 2024: $311 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.08 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $408.59 | 2019-2025 | Rexulti, Abilify Mycite |
| Lundbeck LLC | $279.67 | 2019-2024 | Rexulti |
| Allergan, INC. | $262.08 | 2019-2020 | |
| Axsome Therapeutics, INC. | $224.94 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $199.41 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $196.06 | 2020-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $119.03 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $95.46 | 2023 | Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $94.84 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $73.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $72.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $63.98 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.57 | 2023-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $56.73 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $44.48 | 2019 | |
| Biogen, INC. | $23.53 | 2024 | |
| Ironshore Pharmaceuticals INC. | $22.44 | 2019 | |
| Alkermes, INC. | $22.30 | 2024 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $15.98 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $15.58 | 2023 | Belsomra |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Earle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.